Document Detail

Dose-dense biweekly doxorubicin/docetaxel versus sequential neoadjuvant chemotherapy with doxorubicin/cyclophosphamide/docetaxel in operable breast cancer: second interim analysis.
MedLine Citation:
PMID:  12425756     Owner:  NLM     Status:  MEDLINE    
Timing of systemic treatment in primary operable breast cancer is subject to extensive investigation, suggesting that pathologic complete remission (pCR) might improve survival in this setting. The German Adjuvant Breast Cancer Group previously demonstrated the feasibility of a dose-dense biweekly schedule of 4 cycles doxorubicin 50 mg/m2 and docetaxel 75 mg/m2 (ddAT) +/- tamoxifen in the neoadjuvant setting to yield a pCR of 9.7% (Gepardo trial). Patients assigned to ddAT received prophylactic granulocyte colony-stimulating factor support (5 micro g/kg days 5-10). The current study (GeparDUO) was designed to assess whether the pCR rate, including no viable invasive and preinvasive tumor cells, achieved with ddAT was equivalent to sequential administration of doxorubicin/cyclophosphamide followed by docetaxel (AC-DOC) over 24 weeks in primary operable breast cancer. From June 1999 to September 2001, 913 patients were enrolled in this trial. In total, 395 patients randomized before August 1, 2000, were included in the second interim analysis. Safety data were available from 369 patients (ddAT, n = 191; AC-DOC, n = 178) demonstrating that toxicity of both regimens was tolerable. Grade 3/4 neutropenia occurred in 39.8% of patients receiving ddAT and in 69.3% of patients treated with AC-DOC. Efficacy data were available in 378 patients. A pCR occurred in 14.8% of the primary breast tumors. According to the recommendations of the data monitoring committee, recruitment to the study was halted as of September 2001 (n = 913/1000) due to the significant difference in pCR rates observed between the treatment arms. Surgery was documented in 380 patients. Breast conservation was possible in 288 cases (75.8%). The application of both schedules is safe and feasible in an outpatient setting. Although, results obtained from this interim analysis are encouraging, caution is recommended until the results obtained show statistical difference in pCR.
Christian Jackisch; Gunter von Minckwitz; Holger Eidtmann; Serban Dan Costa; Günther Raab; Jens Uwe Blohmer; Martin Schütte; Bernd Gerber; Elisabeth Merkle; Günther Gademann; Dieter Lampe; Jörn Hilfrich; Augustinus-Harjanto Tulusan; Angelika Caputo; Manfred Kaufmann
Related Documents :
9516596 - Paclitaxel plus doxorubicin in metastatic breast ca: the milan experience.
14533836 - Onycholysis with the appearance of a "sunset" secondary to capecitabine.
12082646 - Current clinical practices for ovarian cancers.
15770536 - Optimizing the treatment of metastatic breast cancer.
21681736 - Physician over-recommendation of mammography for terminally ill women.
8249506 - Diagnostic value of differential brushing of all branches of the bronchi in patients wi...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Clinical breast cancer     Volume:  3     ISSN:  1526-8209     ISO Abbreviation:  Clin. Breast Cancer     Publication Date:  2002 Oct 
Date Detail:
Created Date:  2002-11-11     Completed Date:  2003-04-22     Revised Date:  2013-05-28    
Medline Journal Info:
Nlm Unique ID:  100898731     Medline TA:  Clin Breast Cancer     Country:  United States    
Other Details:
Languages:  eng     Pagination:  276-80     Citation Subset:  IM    
Department of Obstetrics and Gynecology, University of Marburg, Pilgrimstein 3, D-35037 Marburg, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Breast Neoplasms / drug therapy*,  surgery
Chemotherapy, Adjuvant
Cyclophosphamide / administration & dosage
Doxorubicin / administration & dosage
Drug Administration Schedule
Middle Aged
Neoadjuvant Therapy
Paclitaxel / administration & dosage,  analogs & derivatives*
Remission Induction
Treatment Outcome
Reg. No./Substance:
0/Taxoids; 15H5577CQD/docetaxel; 23214-92-8/Doxorubicin; 33069-62-4/Paclitaxel; 50-18-0/Cyclophosphamide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of n...
Next Document:  Expression and regulation of tumor suppressor gene maspin in breast cancer.